What to Track During the First 12 Weeks on a New IBD Medication

Starting a new inflammatory bowel disease medication puts you into a defined window that clinicians call induction, the front-loaded phase when doses come close together and your gastroenterology team decides whether to continue, adjust, or switch. That decision has deadlines written into the drug labels themselves. The vedolizumab label instructs prescribers to discontinue treatment in patients who show no evidence of therapeutic benefit by week 14, and the adalimumab label says to discontinue in adults with ulcerative colitis without evidence of clinical remission by eight weeks. Most of the evidence behind those calls comes from you. Knowing what to track when starting a new IBD medication turns a fuzzy three months into a record your care team can actually use.

Week 0: capture a baseline before the first dose

The single most valuable entry in your tracker is the one you make before treatment starts, because everything afterward is measured against it. Write down your usual stool frequency, whether there is blood, how often urgency wakes you at night, abdominal pain, fatigue, and weight. Record your most recent C-reactive protein and fecal calprotectin values as well. AGA guidance on biomarkers in ulcerative colitis uses a fecal calprotectin threshold of 150 micrograms per gram as the decision point between quiescent and active inflammation, so a starting number gives later results meaning.

Baseline screening also belongs in the record. The infliximab label requires evaluation for active and latent tuberculosis before the first infusion, with treatment of latent infection started first, and the boxed warning covers serious infections and malignancy. Ustekinumab carries the same pre-treatment tuberculosis evaluation requirement. Note the date those tests were done and their results.

Weeks 1 to 4: build a dose calendar that reflects reality

Induction schedules vary enough that a generic reminder app will get them wrong. Infliximab is given at 5 mg per kilogram at weeks 0, 2, and 6, then every eight weeks. Vedolizumab starts with 300 mg intravenously at weeks 0 and 2. Ustekinumab uses a single weight-based infusion followed by a 90 mg subcutaneous dose eight weeks later. Adalimumab for Crohn's disease begins with 160 mg on day 1 and 80 mg on day 15. Risankizumab for Crohn's disease is 600 mg intravenously at weeks 0, 4, and 8, with maintenance beginning at week 12. Upadacitinib is taken orally at 45 mg daily for eight weeks in ulcerative colitis and twelve weeks in Crohn's disease.

Log the date each dose was actually given rather than the date it was scheduled. Delays from insurance authorization, infusion center availability, or a missed pen matter clinically, because gaps in exposure are one reason drug levels fall and antibodies develop.

Weeks 1 to 12: side effects, infections, and the steroid taper

Injection and infusion reactions are common enough to expect and specific enough to describe. In placebo-controlled trials, 20 percent of adalimumab-treated patients developed injection site reactions such as redness, itching, pain, or swelling, compared with 14 percent on placebo, and most were mild. Note what the site looked like, how long it lasted, and whether it worsened with each dose.

Infection signals deserve their own line. Fever, persistent cough, night sweats, new skin sores, or urinary symptoms are the events your team wants reported promptly rather than at the next visit. If you are tapering prednisone at the same time, record the daily dose alongside your symptoms. The 2025 ACG Crohn's disease guideline treats systemic corticosteroids as induction-only agents, recommends limiting use to under three months, and calls for a structured taper. Without a steroid column in your tracker, it is impossible to tell whether feeling well at week 6 reflects the new drug or the steroids still on board.

Weeks 4 to 8: the first honest read on response

This is where a symptom diary earns its keep. STRIDE-II, the international consensus on treat-to-target goals in IBD, sets symptomatic relief and normalization of blood and stool markers as short-term targets, with clinical remission and endoscopic healing as longer-term ones. Stool frequency and rectal bleeding tend to move first, so track them daily as counts rather than impressions. Add urgency, nocturnal bowel movements, pain scores, and fatigue weekly.

Bloodwork joins the picture around this point. In treat-to-target practice, CRP normalization at weeks 8 and 14 after starting therapy has been associated with remission at one year. Some medications carry their own required labs during this stretch. The risankizumab label directs clinicians to evaluate liver enzymes and bilirubin at baseline and through at least 12 weeks of induction, and the upadacitinib label sets thresholds for interrupting treatment based on lymphocyte count, neutrophil count, and hemoglobin. Ask which labs are being drawn, and record the results with their dates.

Weeks 8 to 12: the appointment your notes are feeding

By week 12, most teams reassess formally. Fecal calprotectin measured around this point correlates with longer-term outcomes, and AGA guidance suggests that a level above 150 micrograms per gram in someone with mild residual symptoms warrants endoscopic assessment before therapy is changed. If you are on upadacitinib, a lipid panel is recommended at roughly 12 weeks after starting.

Drug levels may also come up. The AGA guideline on therapeutic drug monitoring suggests reactive testing of anti-tumor necrosis factor drug concentrations and antibodies in patients with active disease, and routine thiopurine methyltransferase testing before starting azathioprine or mercaptopurine. A documented history of missed or delayed doses helps interpret a low level correctly.

Bring three things to that visit: your baseline numbers, your week-by-week symptom counts with the steroid dose alongside them, and a dose calendar showing what was given and when. Those three artifacts answer the questions that determine whether you stay on this medication, escalate the dose, or move on, and they answer them with data instead of memory.